Read Our Report:
Prostate Cancer Screening Report and Recommendations (Adopted November 2015)
Prostate cancer screening is variable and may expose men to increased risk of harm, increased cost, and lower quality of life. This workgroup will identify evidence-based best practice for prostate cancer specific antigen (PSA) testing for prostate cancer screening and propose recommendations along with data-driven implementation strategies to the full Bree Collaborative.
This workgroup met from February to November 2015.
|John Gore, MD, MS||Urologist, clinician, surgeon, researcher||University of Washington Medicine|
|Matt Handley, MD||Associate Medical Director, Quality and Informatics||Group Health Cooperative|
|Leah Hole-Marshall, JD||Medical Administrator||Department of Labor & Industries|
|Steve Lovell||Retired||Patient and Family Advisory Council|
|Rick Ludwig, MD (Chair)||Chief Medical Officer||Providence Accountable Care Organization|
|Bruce Montgomery, MD||Clinical Director of Genitourinary Medical Oncology||Seattle Cancer Care Alliance|
|Eric Wall, MD, MPH||Market Medical Director||UnitedHealthcare|
|Shawn West, MD||Family Physician||Edmonds Family Medicine|
|Jonathan Wright, MD, MS, FACS||Assistant professor of urology/affiliate researcher||University of Washington/Fred Hutchinson Cancer Research Center|